REDX.L Stock - Redx Pharma Plc
Unlock GoAI Insights for REDX.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $4.20M | $18.69M | $10.04M | $5.68M | $3.13M |
| Gross Profit | $3.24M | $18.69M | $10.04M | $5.68M | $2.78M |
| Gross Margin | 77.2% | 100.0% | 100.0% | 100.0% | 88.8% |
| Operating Income | $-33,820,000 | $-16,266,000 | $-19,745,000 | $-8,274,000 | $-7,193,000 |
| Net Income | $-33,156,000 | $-18,005,000 | $-21,576,000 | $-9,213,000 | $-4,318,000 |
| Net Margin | -789.1% | -96.3% | -215.0% | -162.1% | -137.9% |
| EPS | $-0.10 | $-0.06 | $-0.08 | $-0.05 | $-0.03 |
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
Visit WebsiteEarnings History & Surprises
REDX.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Mar 14, 2025 | — | — | — | — |
Q2 2024 | May 15, 2024 | — | — | — | — |
Q1 2024 | Mar 14, 2024 | — | $-0.04 | — | — |
Q2 2023 | May 17, 2023 | — | $-0.06 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.03 | — | — |
Q2 2022 | Jun 23, 2022 | — | $-0.04 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.03 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.05 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.03 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.03 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.02 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.02 | — | — |
Q3 2018 | Sep 30, 2018 | — | $-0.03 | — | — |
Q1 2018 | Mar 31, 2018 | — | $-0.03 | — | — |
Q3 2017 | Sep 30, 2017 | — | $0.01 | — | — |
Q1 2017 | Mar 31, 2017 | — | $0.01 | — | — |
Q3 2016 | Sep 30, 2016 | — | $-0.10 | — | — |
Q1 2016 | Mar 31, 2016 | — | $-0.10 | — | — |
Q3 2015 | Sep 30, 2015 | — | $-0.07 | — | — |
Q1 2015 | Mar 31, 2015 | — | $-0.07 | — | — |
Latest News
Frequently Asked Questions about REDX.L
What is REDX.L's current stock price?
What is the analyst price target for REDX.L?
What sector is Redx Pharma Plc in?
What is REDX.L's market cap?
Does REDX.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to REDX.L for comparison